東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Determinants of AAV Transport across...

Albright, Blake Harris.

FindBook

Google Book

Amazon

博客來

Determinants of AAV Transport across the Blood-Brain Barrier.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Determinants of AAV Transport across the Blood-Brain Barrier./
作者:	Albright, Blake Harris.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
面頁冊數:	133 p.
附註:	Source: Dissertations Abstracts International, Volume: 80-07, Section: B.
Contained By:	Dissertations Abstracts International80-07B.
標題:	Molecular biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10982159
ISBN:	9780438790124

Determinants of AAV Transport across the Blood-Brain Barrier.
Albright, Blake Harris.

Determinants of AAV Transport across the Blood-Brain Barrier. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 133 p.

Source: Dissertations Abstracts International, Volume: 80-07, Section: B.

Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2018.

This item must not be added to any third party search indexes.

Adeno-associated virus (AAV) is currently the most widely used gene therapy vector for treating neurological diseases, showing promising results in preclinical and clinical studies. Nonetheless, many challenges limit effective gene transfer to the central nervous system (CNS) via the vasculature, which requires that AAV vectors cross the blood-brain barrier (BBB). As a consequence of sub-optimal transduction efficiency, current vectors must be administered at high dosages to achieve therapeutic CNS gene transfer and are limited by off-target tissue transduction/sequestration. Thus, developing vectors with improved efficiency and specificity is critical towards achieving widespread and therapeutic gene transfer to the CNS. This requires a better understanding of the structural determinants for AAV tropism and neurovascular transport-which is the primary aim for this dissertation. To achieve this, we generated a chimeric capsid library between two highly homologous serotypes-AAVrh.10, which crosses the BBB, and AAV1, which is limited to the vasculature. Through screening individual variants in vivo, computational analyses, and rational design, we mapped a footprint from the AAVrh.10 capsid which confers BBB transport and widespread CNS transduction when grafted onto AAV1. In this way, we engineered the novel and neurotropic AAV1RX capsid, which mediates robust gene transfer throughout the brain, with reduced glial and endothelial transduction, and is detargeted from peripheral tissues (i.e. liver). We hypothesized that the 1RX footprint may alter capsid-sialic acid (SIA) interactions in a way that promotes BBB traversal and CNS transduction. We tested this through functional characterization of several capsid variants with alterations in their SIA binding site. These capsids were functionally grouped according to their differential dependencies on cell-surface SIA for in vitro transduction and binding. Further evaluation in vivo revealed an inverse correlation between capsid-SIA interactions and BBB transport/CNS transduction. These experiments suggest that more moderate capsid-SIA interactions may facilitate, though only partially explain, the 1RX phenotype. Nonetheless, this led us to propose a Goldilocks model wherein the ideal glycan binding affinity, in conjunction with other contributing factors, impacts BBB traversal and CNS transduction. Thus, this dissertation sheds light on AAV determinants for BBB transport, providing a structure-guided platform for engineering improved CNS-targeted AAV vectors.

ISBN: 9780438790124Subjects--Topical Terms:

517296
Molecular biology.

Determinants of AAV Transport across the Blood-Brain Barrier.
LDR:03746nmm a2200349 4500 001 2207246
005 20190916101807.5
008 201008s2018 ||||||||||||||||| ||eng d
020 $a 9780438790124
035 $a (MiAaPQ)AAI10982159
035 $a (MiAaPQ)unc:18256
035 $a AAI10982159
040 $a MiAaPQ $c MiAaPQ
100 1 $a Albright, Blake Harris. $3 3434205
245 1 0 $a Determinants of AAV Transport across the Blood-Brain Barrier.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 133 p.
500 $a Source: Dissertations Abstracts International, Volume: 80-07, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Asokan, Aravind;Swanstrom, Ronald.
502 $a Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2018.
506 $a This item must not be added to any third party search indexes.
506 $a This item must not be sold to any third party vendors.
520 $a Adeno-associated virus (AAV) is currently the most widely used gene therapy vector for treating neurological diseases, showing promising results in preclinical and clinical studies. Nonetheless, many challenges limit effective gene transfer to the central nervous system (CNS) via the vasculature, which requires that AAV vectors cross the blood-brain barrier (BBB). As a consequence of sub-optimal transduction efficiency, current vectors must be administered at high dosages to achieve therapeutic CNS gene transfer and are limited by off-target tissue transduction/sequestration. Thus, developing vectors with improved efficiency and specificity is critical towards achieving widespread and therapeutic gene transfer to the CNS. This requires a better understanding of the structural determinants for AAV tropism and neurovascular transport-which is the primary aim for this dissertation. To achieve this, we generated a chimeric capsid library between two highly homologous serotypes-AAVrh.10, which crosses the BBB, and AAV1, which is limited to the vasculature. Through screening individual variants in vivo, computational analyses, and rational design, we mapped a footprint from the AAVrh.10 capsid which confers BBB transport and widespread CNS transduction when grafted onto AAV1. In this way, we engineered the novel and neurotropic AAV1RX capsid, which mediates robust gene transfer throughout the brain, with reduced glial and endothelial transduction, and is detargeted from peripheral tissues (i.e. liver). We hypothesized that the 1RX footprint may alter capsid-sialic acid (SIA) interactions in a way that promotes BBB traversal and CNS transduction. We tested this through functional characterization of several capsid variants with alterations in their SIA binding site. These capsids were functionally grouped according to their differential dependencies on cell-surface SIA for in vitro transduction and binding. Further evaluation in vivo revealed an inverse correlation between capsid-SIA interactions and BBB transport/CNS transduction. These experiments suggest that more moderate capsid-SIA interactions may facilitate, though only partially explain, the 1RX phenotype. Nonetheless, this led us to propose a Goldilocks model wherein the ideal glycan binding affinity, in conjunction with other contributing factors, impacts BBB traversal and CNS transduction. Thus, this dissertation sheds light on AAV determinants for BBB transport, providing a structure-guided platform for engineering improved CNS-targeted AAV vectors.
590 $a School code: 0153.
650 4 $a Molecular biology. $3 517296
650 4 $a Genetics. $3 530508
650 4 $a Virology. $3 642304
690 $a 0307
690 $a 0369
690 $a 0720
710 2 $a The University of North Carolina at Chapel Hill. $b Genetics and Molecular Biology. $3 3173502
773 0 $t Dissertations Abstracts International $g 80-07B.
790 $a 0153
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10982159